Skip to main content
. 2022 May 15;23(10):5518. doi: 10.3390/ijms23105518

Table 2.

Reasonable choices for overlapping diseases.

Typical PSO Typical AD AD-PSO
Overlapping
Treatment
Topical agents Corticosteroids Corticosteroids Corticosteroids
Vitamin D3 analog Calcineurin inhibitor Calcineurin inhibitor
Retinoids PDE4 inhibitor
(crisaborole)
JAK inhibitor
(ruxolitinib)
Tar
Calcineurin inhibitor *
Conventional oral medications Methotrexate
Acitretin
Cyclosporin		 Methotrexate *
Azathioprine *
Cyclosporin		 Methotrexate
Cyclosporin
Phototherapy NBUVB # NBUVB # NBUVB #
Biologics IL-12/23i, IL-17i,
IL-23i, TNF-αi		 IL-4/13i, IL-13i IL-12/23i ?
Systemic small
molecular drugs 		PDE4 inhibitor
(apremilast)
JAK inhibitor
(upadacitinib) **		 JAK inhibitor
(baricitinib,
upadacitinib,
abrocitinib)		 JAK inhibitor (upadacitinib) **

* Not licensed, but generally listed in worldwide treatment guidelines. # NBUVB: narrowband ultraviolet B. ? Well-tolerated but without efficacy in atopic dermatitis [93,94]. ** Licensed for psoriatic arthritis.